ENTITY
Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals (PAR AU)

22
Analysis
Health Care • Australia
Paradigm Biopharmaceuticals Limited operates as a biopharmaceutical company. The Company develops PPS drug to treat respiratory diseases such as allergic asthma, allergic rhinitis, and chronic obstructive pulmonary. Paradigm Biopharmaceuticals offers its services in Australia.
more
Exchange Announcement • 15 Oct 2026 11:57

PPS Shows Significant Pain Benefit in Rest of World Analysis

Exchange Announcement • 12 Oct 2026 12:12

Expiry of PAROB Listed Options

Exchange Announcement • 08 Oct 2026 14:31

Notification of cessation of securities - PAR

Exchange Announcement • 08 Oct 2026 14:24

Update on Data Review and Convertible note redemption

Exchange Announcement • 30 Sep 2026 07:56

Continuation of Suspension from Quotation

x